Literature DB >> 29535913

Current standards for clinical management of small cell lung cancer.

Anna F Farago1, Florence K Keane2.   

Abstract

Small cell lung cancer (SCLC) is an aggressive high-grade neuroendocrine carcinoma. Despite over 30 years of clinical research, little progress has been made in the management of SCLC, and outcomes remain poor. Here, we review the current clinical standards for management of SCLC and the data supporting these strategies.

Entities:  

Keywords:  Small cell lung cancer (SCLC); chemotherapy; radiation

Year:  2018        PMID： 29535913      PMCID： PMC5835595          DOI： 10.21037/tlcr.2018.01.16

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


  67 in total

1.  A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer.

Authors:  Taofeek K Owonikoko; Madhusmita Behera; Zhengjia Chen; Chandar Bhimani; Walter J Curran; Fadlo R Khuri; Suresh S Ramalingam
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

Review 2.  Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer.

Authors:  Daniel B Fried; David E Morris; Charles Poole; Julian G Rosenman; Jan S Halle; Frank C Detterbeck; Thomas A Hensing; Mark A Socinski
Journal:  J Clin Oncol       Date:  2004-12-01       Impact factor: 44.544

3.  Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.

Authors:  Stein Sundstrøm; Roy M Bremnes; Stein Kaasa; Ulf Aasebø; Reidulv Hatlevoll; Ragnar Dahle; Nils Boye; Mari Wang; Tor Vigander; Jan Vilsvik; Eva Skovlund; Einar Hannisdal; Steinar Aamdal
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

4.  Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

Authors:  Mary E R O'Brien; Tudor-Eliade Ciuleanu; Hristo Tsekov; Yaroslav Shparyk; Branka Cuceviá; Gabor Juhasz; Nicholas Thatcher; Graham A Ross; Graham C Dane; Theresa Crofts
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

5.  Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.

Authors:  David R Spigel; Peter M Townley; David M Waterhouse; Liang Fang; Ibrahim Adiguzel; Jane E Huang; David A Karlin; Leonardo Faoro; Frank A Scappaticci; Mark A Socinski
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

6.  Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.

Authors:  M Catherine Pietanza; Kyuichi Kadota; Kety Huberman; Camelia S Sima; John J Fiore; Dyana K Sumner; William D Travis; Adriana Heguy; Michelle S Ginsberg; Andrei I Holodny; Timothy A Chan; Naiyer A Rizvi; Christopher G Azzoli; Gregory J Riely; Mark G Kris; Lee M Krug
Journal:  Clin Cancer Res       Date:  2012-01-06       Impact factor: 12.531

7.  Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extracranial Irradiation for Extensive-Disease Small Cell Lung Cancer (ED SCLC): NRG Oncology RTOG 0937.

Authors:  Elizabeth M Gore; Chen Hu; Alexander Y Sun; Daniel F Grimm; Suresh S Ramalingam; Neal E Dunlap; Kristin A Higgins; Maria Werner-Wasik; Aaron M Allen; Puneeth Iyengar; Gregory M M Videtic; Russell K Hales; Ronald C McGarry; James J Urbanic; Anthony T Pu; Candice A Johnstone; Volker W Stieber; Rebecca Paulus; Jeffrey D Bradley
Journal:  J Thorac Oncol       Date:  2017-06-23       Impact factor: 15.609

8.  Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial.

Authors:  Cécile Le Péchoux; Ariane Dunant; Suresh Senan; Aaron Wolfson; Elisabeth Quoix; Corinne Faivre-Finn; Tudor Ciuleanu; Rodrigo Arriagada; Richard Jones; Rinus Wanders; Delphine Lerouge; Agnès Laplanche
Journal:  Lancet Oncol       Date:  2009-04-20       Impact factor: 41.316

9.  CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.

Authors:  N Masuda; M Fukuoka; Y Kusunoki; K Matsui; N Takifuji; S Kudoh; S Negoro; M Nishioka; K Nakagawa; M Takada
Journal:  J Clin Oncol       Date:  1992-08       Impact factor: 44.544

Review 10.  Staging and imaging of small cell lung cancer.

Authors:  Gregory P Kalemkerian
Journal:  Cancer Imaging       Date:  2012-01-12       Impact factor: 3.909
View more
  49 in total

1.  Sleep better on combination therapy: SLFN11 predicts response to veliparib and temozolomide in recurrent small cell lung cancer.

Authors:  Chen Zhao; Nobuyuki Takahashi; Arun Rajan
Journal:  Transl Lung Cancer Res       Date:  2018-12

2.  Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.

Authors:  Xiangyu Zhang; Liang Zeng; Yizhi Li; Qinqin Xu; Haiyan Yang; Analyn Lizaso; Xinru Mao; Ren'an Jin; Yu Zeng; Qinglin Li; Jianbo Wang; Yang Li; Yongchang Zhang; Nong Yang
Journal:  Cancer Immunol Immunother       Date:  2021-02-10       Impact factor: 6.968

3.  Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer.

Authors:  Anna F Farago; Beow Y Yeap; Marcello Stanzione; Yin P Hung; Rebecca S Heist; J Paul Marcoux; Jun Zhong; Deepa Rangachari; David A Barbie; Sarah Phat; David T Myers; Robert Morris; Marina Kem; Taronish D Dubash; Elizabeth A Kennedy; Subba R Digumarthy; Lecia V Sequist; Aaron N Hata; Shyamala Maheswaran; Daniel A Haber; Michael S Lawrence; Alice T Shaw; Mari Mino-Kenudson; Nicholas J Dyson; Benjamin J Drapkin
Journal:  Cancer Discov       Date:  2019-08-15       Impact factor: 39.397

4.  Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.

Authors:  Charles M Rudin; Mark M Awad; Alejandro Navarro; Maya Gottfried; Solange Peters; Tibor Csőszi; Parneet K Cheema; Delvys Rodriguez-Abreu; Mirjana Wollner; James Chih-Hsin Yang; Julien Mazieres; Francisco J Orlandi; Alexander Luft; Mahmut Gümüş; Terufumi Kato; Gregory P Kalemkerian; Yiwen Luo; Victoria Ebiana; M Catherine Pietanza; Hye Ryun Kim
Journal:  J Clin Oncol       Date:  2020-05-29       Impact factor: 44.544

5.  Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC).

Authors:  Shirish M Gadgeel; Nathan A Pennell; Mary Jo Fidler; Balazs Halmos; Philip Bonomi; James Stevenson; Bryan Schneider; Ammar Sukari; Jaclyn Ventimiglia; Wei Chen; Cathy Galasso; Antoinette Wozniak; Julie Boerner; Gregory P Kalemkerian
Journal:  J Thorac Oncol       Date:  2018-07-17       Impact factor: 15.609

6.  ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line.

Authors:  Anna F Farago; Benjamin J Drapkin; Jose Antonio Lopez-Vilarino de Ramos; Carlos M Galmarini; Rafael Núñez; Carmen Kahatt; Luis Paz-Ares
Journal:  Future Oncol       Date:  2018-10-26       Impact factor: 3.404

7.  Diagnostic accuracy of human epididymis secretory protein 4 for lung cancer: a systematic review and meta-analysis.

Authors:  Li Yan; Zhi-De Hu
Journal:  J Thorac Dis       Date:  2019-07       Impact factor: 2.895

8.  Irinotecan, topotecan, paclitaxel or docetaxel for second-line treatment of small cell lung cancer: a single-center retrospective study of efficiency comparation and prognosis analysis.

Authors:  Yuan Zhao; Bing Wan; Tianli Zhang; Yangyang Xu; Hongbing Liu; Tangfeng Lv; Fang Zhang; Ping Zhan; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2019-12

Review 9.  Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights.

Authors:  Catherine B Meador; Aaron N Hata
Journal:  Pharmacol Ther       Date:  2020-03-06       Impact factor: 12.310

10.  RNA sequencing analysis of small cell lung cancer reveals candidate chemotherapy insensitivity long noncoding RNAs and microRNAs.

Authors:  Peng Kuang; Peixin Chen; Lei Wang; Wei Li; Bin Chen; Yu Liu; Yi Xu; Hao Wang; Sha Zhao; Lingyun Ye; Feng Yu; Hongbin Ji; Yayi He
Journal:  Ann Transl Med       Date:  2020-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.